| Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study NA Kennedy, GA Heap, HD Green, B Hamilton, C Bewshea, GJ Walker, ... The lancet Gastroenterology & hepatology 4 (5), 341-353, 2019 | 657 | 2019 |
| HLA-DQA1* 05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn’s disease A Sazonovs, NA Kennedy, L Moutsianas, GA Heap, DL Rice, M Reppell, ... Gastroenterology 158 (1), 189-199, 2020 | 353 | 2020 |
| British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic NA Kennedy, GR Jones, CA Lamb, R Appleby, I Arnott, RM Beattie, ... Gut 69 (6), 984-990, 2020 | 299 | 2020 |
| HLA-DQA1–HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants GA Heap, MN Weedon, CM Bewshea, A Singh, M Chen, JB Satchwell, ... Nature genetics 46 (10), 1131-1134, 2014 | 219 | 2014 |
| IBD prevalence in Lothian, Scotland, derived by capture–recapture methodology GR Jones, M Lyons, N Plevris, PW Jenkinson, C Bisset, C Burgess, S Din, ... Gut 68 (11), 1953-1960, 2019 | 201 | 2019 |
| Dynamics of colon monocyte and macrophage activation during colitis GR Jones, CC Bain, TM Fenton, A Kelly, SL Brown, AC Ivens, MA Travis, ... Frontiers in Immunology 9, 2764, 2018 | 160 | 2018 |
| COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study JL Alexander, NA Kennedy, H Ibraheim, S Anandabaskaran, A Saifuddin, ... The lancet Gastroenterology & hepatology 7 (4), 342-352, 2022 | 142 | 2022 |
| Macrophages in intestinal homeostasis and inflammatory bowel disease LM Hegarty, GR Jones, CC Bain Nature Reviews Gastroenterology & Hepatology 20 (8), 538-553, 2023 | 105 | 2023 |
| Mechanism of association between BMI and dysfunction of the gastro-oesophageal barrier in patients with normal endoscopy MH Derakhshan, EV Robertson, J Fletcher, GR Jones, YY Lee, AA Wirz, ... Gut 61 (3), 337-343, 2012 | 97 | 2012 |
| Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab S Lin, NA Kennedy, A Saifuddin, DM Sandoval, CJ Reynolds, RC Seoane, ... Nature communications 13 (1), 1379, 2022 | 87 | 2022 |
| A dominant role for the methyl-CpG-binding protein Mbd2 in controlling Th2 induction by dendritic cells PC Cook, H Owen, AM Deaton, JG Borger, SL Brown, T Clouaire, ... Nature communications 6 (1), 6920, 2015 | 85 | 2015 |
| Association between level of fecal calprotectin and progression of Crohn's disease NA Kennedy, GR Jones, N Plevris, R Patenden, ID Arnott, CW Lees Clinical Gastroenterology and Hepatology 17 (11), 2269-2276. e4, 2019 | 81 | 2019 |
| Higher anti-tumor necrosis factor levels are associated with perianal fistula healing and fistula closure in Crohn’s disease N Plevris, PW Jenkinson, ID Arnott, GR Jones, CW Lees European journal of gastroenterology & hepatology 32 (1), 32-37, 2020 | 65 | 2020 |
| The ACE (albumin, CRP and endoscopy) index in acute colitis: a simple clinical index on admission that predicts outcome in patients with acute ulcerative colitis RK Grant, GR Jones, N Plevris, RW Lynch, PW Jenkinson, CW Lees, ... Inflammatory bowel diseases 27 (4), 451-457, 2021 | 62 | 2021 |
| COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre … JL Alexander, Z Liu, DM Sandoval, C Reynolds, H Ibraheim, ... The Lancet Gastroenterology & Hepatology 7 (11), 1005-1015, 2022 | 57 | 2022 |
| Real-world effectiveness and safety of vedolizumab for the treatment of inflammatory bowel disease: the Scottish vedolizumab cohort N Plevris, CS Chuah, RM Allen, ID Arnott, PN Brennan, S Chaudhary, ... Journal of Crohn's and Colitis 13 (9), 1111-1120, 2019 | 49 | 2019 |
| Systematic review: the use of thiopurines or anti‐TNF in post‐operative Crohn's disease maintenance–progress and prospects GR Jones, NA Kennedy, CW Lees, ID Arnott, J Satsangi Alimentary pharmacology & therapeutics 39 (11), 1253-1265, 2014 | 49 | 2014 |
| The transcription factor EGR2 is indispensable for tissue-specific imprinting of alveolar macrophages in health and tissue repair J McCowan, F Fercoq, PM Kirkwood, W T’jonck, LM Hegarty, CM Mawer, ... Science immunology 6 (65), eabj2132, 2021 | 43 | 2021 |
| Normalization of fecal calprotectin within 12 months of diagnosis is associated with reduced risk of disease progression in patients with Crohn’s disease N Plevris, J Fulforth, M Lyons, SI Siakavellas, PW Jenkinson, CS Chuah, ... Clinical Gastroenterology and Hepatology 19 (9), 1835-1844. e6, 2021 | 40 | 2021 |
| BMI is superior to symptoms in predicting response to proton pump inhibitor: randomised trial in patients with upper gastrointestinal symptoms and normal endoscopy J Fletcher, MH Derakhshan, GR Jones, AA Wirz, KEL McColl Gut 60 (4), 442-448, 2011 | 39 | 2011 |
